Yidu Tech Reports Record-Breaking Interim Results for FY2026: Adjusted EBITDA Doubles, New Orders Surge, Near Breakeven, and Large Models Achieve Multi-Scenario Commercialization

On November 27, Yidu Tech (2158.HK) released its interim results announcement for the fiscal year 2026 and held an earnings conference call. During the reporting period, the company’s business maintained healthy growth,Total revenue climbed to RMB 358 million, a year-on-year increase of 8.7%.. Notably, the company’s earnings quality and operational efficiency have improved significantly: its existing businessAdjusted EBITDA Doubled Year-over-Year, approximately RMB 54 million,The financial statements achieved near break-even, a year ahead of the company management’s previous expectations.

Strong Business Growth Momentum,The value of new orders in the core business segment also showed substantial growth.Among them, the big data platform and solutions segment saw new ordersYear-on-year growth of 19.7%, New Orders in the Life Sciences Solutions SegmentYear-on-year growth reached 61.1%。

Management stated at the meeting, “Currently, the company’sLarge model technology has entered a new phase of “multi-point blossoming and large-scale implementation”. This assessment is based on implementation across three dimensions: first, deep adoption in top-tier hospitals, with the company’s AI middle platform deployed in over 30 Grade A tertiary hospitals, and the Doctor Copilot achieving nearly 1,000 high-frequency calls per day at a single hospital; second, precise empowerment of key specialties, with a significant improvement in the accuracy of the TNM staging assessment agent; and third, integration of expertise from leading specialists, as the company leverages physicians’ “digital twins” to extend experts’ clinical experience to serve patients more broadly.”

As the company’s core algorithmic engine, YiduCore achieved breakthrough progress during the reporting period. By leveraging a reinforcing closed loop of “data-driven algorithms, algorithm-empowered scenarios, and scenario-fed data,” it has continuously enhanced the precision of medical insights and the intelligence level of its algorithms.As of September 30, 2025, YiduCore had cumulatively processed and analyzed nearly 7 billion authorized medical records covering over 1.3 billion patient visits, spanning more than 10,000 hospitals. Its disease knowledge graph basically covers all known diseases, and its specialized disease databases have expanded to cover 98 disease types.

Meanwhile, Yidu Tech continues to enhance the performance of its large medical models. To address the industry-wide challenge of “hallucinations” in large models, the company employs measures such as optimized model training, enhanced knowledge integration, improved supervision mechanisms, and strengthened engineering controls.Keep the hallucination rate below 1%.Meanwhile, Yidu Tech has independently developed the MED-RAG architecture, enabling precise retrieval and efficient reasoning of complex medical knowledge. In the field of oncology diagnosis and treatment, the T-stage accuracy of Yidu Tech’s TNM staging assessment agent has increased from 58% to 90%, and N-stage accuracy from 62% to 80%, reaching the diagnostic level of chief physicians, thereby providing strong support for precision oncology care.

Our cutting-edge technical capabilities have also gained industry recognition, winning the championship in the “Automatic Generation of Medical NLP Code Evaluation” and the “Best Paper Award” at the 11th China Health Information Processing Conference (CHIP 2025).

Centered on the “medical care–pharmaceuticals–insurance–patients” full-chain ecosystem, the company’s three major business segments are demonstrating a positive development trend characterized by “deep penetration, broad coverage, and strong implementation.”

Big Data Platforms and Solutions (AI for Medical)SectionRevenue reached RMB 153 million, a year-on-year increase of 14.6%.As of September 30, 2025, the Company has provided solutions to 127 top-tier hospitals in China and 44 regulatory agencies and policymakers. Driven by the dual engines of “data elements × AI technology,” the Company continues to strengthen its data intelligence foundation while accelerating the large-scale deployment of intelligent applications, thereby achieving value penetration from institutions to disciplines and ultimately to individuals. At a cancer prevention and treatment center in South China, Yidu Tech’s Doctor Copilot has recorded nearly 1,000 daily calls, covering approximately 70% of medical staff, and has assisted physicians in serving over 31,000 patient visits cumulatively.

Life Science Solutions (AI for Life Science)Segment revenue reached RMB 138 million. The company is committed to providing AI-driven intelligent services covering the entire product lifecycle for life science clients, with 17 of the top 20 multinational pharmaceutical companies as its customers. During the reporting period, the company successfully supported the accelerated approval and market launch of multiple first-in-class innovative drugs, including the world’s first topical gel formulation for infantile hemangioma and a first-in-class drug for chronic hepatitis B. In frontier areas such as pediatric rare diseases and cell therapy, the company’s real-world evidence (RWE) studies have also achieved significant breakthroughs. Furthermore, Yidu Tech won bids for two major projects commissioned by the National Healthcare Security Administration, gaining recognition for its “AI + Medical Insurance” capabilities.

Health Management Platform and Solutions (AI for Care)Sector Performance Shines,Revenue reached RMB 66.67 million, a year-on-year increase of 30.3%.CompanyMaintain a leading position in the “Huiminbao” business in core cities,CompletedServed as the primary operating platform for “Shenzhen Huimin Bao” for three consecutive years and for “Beijing Puhui Health Insurance” for five consecutive yearsAmong these, the “Shenzhen Huiminbao” plan saw its number of insured participants exceed 6.15 million during the reporting period, setting a new historical record, with cumulative services provided to over 18 million person-times across three years. AI technology has significantly improved service efficiency: more than 85% of compensated claims under the “Beijing Puhui Health Insurance” were settled through expedited claims processing, reducing claims processing time by 60%–70%. The accuracy rate of AI-powered customer service exceeded 97%, with an independent online handling rate of 93%. To date, the company has been deeply involved in “Huiminbao” projects in 13 cities across five provinces, cumulatively serving over 40 million insured individuals.

In the area of chronic disease management, the company’s digital therapeutic solution for diabetes has been gradually expanded from the initial pilot region of Lingshui to Sanya, Wanning, Qionghai, Wenchang, and other areas. Nearly 100,000 patients have been enrolled and managed under this program, with the fasting blood glucose compliance rate improving by 27.04% compared to baseline. As of the end of the reporting period, the number of active transacting users on the health management platform exceeded 22 million.

Currently, medical artificial intelligence is entering a new cycle characterized by a shift from building technical capabilities to systematic empowerment. Yidu Tech’s performance in the first half of fiscal year 2026 has validated the company’s strategic direction and its core value within the full-chain ecosystem encompassing “healthcare providers, pharmaceutical companies, insurers, and patients.” Looking ahead, we will continue to leverage YiduCore as our foundation, deepen the integration of large language model technologies with real-world scenarios, and actively participate in building inclusive, efficient, and collaborative medical AI infrastructure. Management stated, “We believe that ample cash reserves, continuously optimized operational efficiency, and a clear market strategy will support us in seizing broad future market opportunities, achieving high-quality and sustainable growth, and creating long-term value for shareholders, customers, and society.”